People who have just one or two drinks per day are not protected against endocrine conditions such as obesity and type 2 diabetes, according to a new study published in the Endocrine Society’s Journal of Clinical Endocrinology & Metabolism. Alcohol consumption is a significant public health concern because it is related to many medical conditions such as...
People with obesity may have lower work productivity due to increased risk of illness, contributing to increased costs for employers, according to industry-supported research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting, in Chicago, Ill. Obesity is a significant public health issue affecting approximately 42% of people in the United States. Employees...
Tirzepatide – the dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection used to treat type 2 diabetes – is safe and has a tolerable adverse event (AE) profile in its role in the management of T2D, and possibly obesity, according to a study recently published in the Journal of the...
Weight loss achieved through the use of a combination of anti-obesity medications (AOMs) can approach the reduction seen in bariatric surgery, according to a paper recently published in JCEM Case Reports. Researchers led by Priya N. Patel, MD, of the Center for Pediatric Obesity Medicine at the University of Minnesota Medical School in Minneapolis point...
Maria T. Balhara discusses her ENDO 2023 sessions on food’s impact on human health A three-session symposium on our everchanging food environment, “Impact of the Changes in Food Environment in the Development of Obesity,” looks at endocrine-disrupting chemicals, climate change, and processing methods and how these factors impact endocrine health, specifically obesity. Endocrine News talks...
The popularity of GLP-1 agonists to treat obesity has been skyrocketing in recent months, leading to both shortages and price increases. However, as more patients make their voices heard and doctors begin to prescribe them, obesity could become easier to treat or even cure. Thanksgiving is a time for family, fellowship, and food. But for...
Obesity is a public health crisis in the United States. As a prevalent and costly disease, it puts adults and children at risk for many comorbid conditions, reduces productivity, and impairs military readiness. As the 118th Congress gets underway, several congressional leaders and committees are interested in addressing obesity in America. In March, as part...
Fibroblast growth factor 21 (FGF21) protects mice against ethanol-induced loss of balance and righting reflex, according to a study recently published in Cell Metabolism. Researchers led by Steven Kliewer, PhD, and David Mangelsdorf, PhD, both of the University of Texas Southwestern Medical Center in Dallas, point out that simple sugars in ripening fruits and nectars are a...
Tirzepatide – the dual glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection used to treat type 2 diabetes – is safe and has a tolerable adverse event (AE) profile in its role in the management of T2D, and possibly obesity, according to a study recently published in the Journal of the...
Maria T. Balhara discusses her ENDO 2023 sessions on food’s impact on human health A three-session symposium on our everchanging food environment, “Impact of the Changes in Food Environment in the Development of Obesity,” looks at endocrine-disrupting chemicals, climate change, and processing methods and how these factors impact endocrine health, specifically obesity. Endocrine News talks...
